Cannabinoids reduce cAMP levels in the striatum of freely moving rats: an in vivo microdialysis study.
The cannabinoid receptor subtype 1 (CB1R) is a member of the G(i)-protein-coupled receptor family and cannabinoid signaling is largely dependent on the suppression of adenylyl cyclase-catalyzed cAMP production. In cell lines transfected with the CB1R or in native tissue preparations, treatment with cannabinoid agonists reduces both basal and forskolin-stimulated cAMP synthesis. We measured extracellular cAMP concentrations in the striatum of freely moving rats utilizing microdialysis to determine if changes in cAMP concentrations in response to CB1R agonists can be monitored in vivo. Striatal infusion of the CB1R agonist WIN55,212-2 (100 microM or 1 mM), dose-dependently decreased basal and forskolin-stimulated extracellular cAMP. These effects were reversed by co-infusion of the CB1R antagonist SR141716A (30 microM), which alone had no effect up to the highest concentration tested (300 microM). These data indicate that changes in extracellular cAMP concentrations in response to CB1R stimulation can be monitored in vivo allowing the study of cannabinoid signaling in the whole animal.
Wade
Mark R
MR
Lilly Research Laboratories, Neuroscience Discovery, Eli Lilly and Company, Indianapolis, IN 46285-0510, USA.
Tzavara
Eleni T
ET
Nomikos
George G
GG
D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D008297:Male; D017551:Microdialysis / Q000379:methods*; D009068:Movement / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar
D002186:Cannabinoids; D000242:Cyclic AMP